Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ALX Oncology Holdings's Enterprise Value is $-91.70 Mil.
ALX Oncology Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-133.12 Mil. Therefore, ALX Oncology Holdings's EV-to-EBIT ratio for today is 0.69.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, ALX Oncology Holdings's Enterprise Value is $-91.70 Mil.
ALX Oncology Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $-132.25 Mil. Therefore, ALX Oncology Holdings's EV-to-EBITDA ratio for today is 0.69.
ALX Oncology Holdings Enterprise Value Historical Data
The historical data trend for ALX Oncology Holdings's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ALX Oncology Holdings's Enterprise Value
For the Biotechnology subindustry, ALX Oncology Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALX Oncology Holdings's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's Enterprise Value distribution charts can be found below:
* The bar in red indicates where ALX Oncology Holdings's Enterprise Value falls into.
ALX Oncology Holdings Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
ALX Oncology Holdings's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALX Oncology Holdings (NAS:ALXO) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
ALX Oncology Holdings's current Enterprise Value is $-91.70 Mil.
ALX Oncology Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-133.12 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
ALX Oncology Holdings's EV-to-EBITDA for today is:
ALX Oncology Holdings's current Enterprise Value is $-91.70 Mil.
ALX Oncology Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-132.25 Mil.
ALX Oncology Holdings's current Enterprise Value is $-91.70 Mil.
ALX Oncology Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
ALX Oncology Holdings's current Enterprise Value is $-91.70 Mil.
ALX Oncology Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-122.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALX Oncology Holdings Enterprise Value Related Terms
Thank you for viewing the detailed overview of ALX Oncology Holdings's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALXO has been successfully added to your 